Australian researchers have developed a new COVID-19 vaccine called CoVEXS5, which offers broad protection against multiple coronavirus variants, including the Omicron XBB.1.5.

The research team is actively working on further testing and development of CoVEXS5 to advance its potential use.

The development of CoVEXS5 was funded by the Coalition for Epidemic Preparedness Innovations (CEPI), an organization dedicated to accelerating vaccine development for pandemic threats and ensuring global accessibility.

The vaccine includes Sepivac SWE, an open-access adjuvant that enhances immune responses and promotes equitable global vaccine manufacturing and distribution, especially in low and middle-income countries.

In laboratory studies with mice, CoVEXS5 reduced virus levels in the lungs by approximately 99.9%, demonstrating its strong protective effect.

The vaccine has been shown to trigger high levels of virus-blocking antibodies and activate immune T-cells in the lungs, which are crucial for defending against respiratory viruses.

Created by scientists at the Centenary Institute and the University of Sydney, CoVEXS5 features a unique spike protein that merges elements from several coronaviruses, helping the immune system recognize a wider range of virus types.

Experts highlight that the open-access nature of Sepivac SWE can facilitate vaccine equity worldwide, making it a significant component of the vaccine's design.

Researchers emphasize that CoVEXS5 prompts the immune system to produce high levels of virus-blocking antibodies and activates T-cells in the lungs, strengthening defenses against respiratory viruses.

Amidst ongoing winter 2025, Australia has reported over 115,000 COVID-19 cases, with new Omicron subvariants contributing to increased infections and hospitalizations.

Scientists believe that this innovative vaccine approach could help prepare the immune system for future coronavirus threats, making it a promising tool in ongoing pandemic management.